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Abstract: Variants in the APOE gene region may explain ethnic differences in the association of
Alzheimer’s disease (AD) with ε4. Ethnic differences in allele frequencies for three APOE region SNPs
(single nucleotide polymorphisms) were identified and tested for association in 19,398 East Asians
(EastA), including Koreans and Japanese, 15,836 European ancestry (EuroA) individuals, and 4985
African Americans, and with brain imaging measures of cortical atrophy in sub-samples of Koreans
and EuroAs. Among ε4/ε4 individuals, AD risk increased substantially in a dose-dependent manner
with the number of APOE promoter SNP rs405509 T alleles in EastAs (TT: OR (odds ratio) = 27.02,
p = 8.80 × 10−94; GT: OR = 15.87, p = 2.62 × 10−9) and EuroAs (TT: OR = 18.13, p = 2.69 × 10−108; GT:
OR = 12.63, p = 3.44 × 10−64), and rs405509-T homozygotes had a younger onset and more severe
cortical atrophy than those with G-allele. Functional experiments using APOE promoter fragments
demonstrated that TT lowered APOE expression in human brain and serum. The modifying effect of
rs405509 genotype explained much of the ethnic variability in the AD/ε4 association, and increasing
APOE expression might lower AD risk among ε4 homozygotes.
Keywords: APOE; promoter polymorphism; Alzheimer’s disease; ethnic variability; brain atrophy;
genetic association
1. Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, characterized clinically by
dementia and memory loss. It is the most common cause of dementia in the elderly, accounting 60–80%
of cases, and it has become a global health issue [1]. The prevalence of AD has been estimated to be
approximately 13% among persons over age 65 and 45% among those over age 85 [2]. The hallmark
neuropathological features of AD include senile plaques containing oligomeric amyloid-β (Aβ42) and
neurofibrillary tangles composed of decomposed hyperphosphorylated tau protein (p-tau). AD patients
display a substantially reduced hippocampal volume measured by brain imaging and have reduced
Aβ42 but increased tau and p-tau levels in cerebrospinal fluid (CSF) [3,4].
The apolipoprotein E (APOE) ε4 allele is the most established genetic risk factor for the common
late-onset form of AD [5–7]. The ε4 is typically present in over 40% of AD patients in European ancestry
(EuroA) populations, but in less than 25% of cognitively normal controls [8]. Previous studies have
shown that ε4 is associated with a reduction in the age at onset of AD symptoms by 5–15 years in
a dose-dependent manner [6,9,10]. The less common ε2 allele is protective against AD [10,11]. There is
disagreement about the effect of ε4 on cognitive decline, with some studies suggesting a positive
correlation [12–16] and others showing no effect [17–19]. Curiously, there are also reports of slower
cognitive decline among ε4 carriers [20]. In spite of these controversial findings, there is consistent
J. Clin. Med. 2019, 8, 1236 3 of 19
evidence from studies of cognitively normal individuals showing that ε4 homozygotes, but not ε4
heterozygotes, have smaller hippocampal volumes than persons lacking the ε4 allele [21–23].
The strength of the ε4 association with AD varies widely across ethnic groups with a smaller effect
among African Americans (AA) [24–26] and Hispanics [10,26], but a higher effect among Japanese
compared to EuroAs [10]. This disparity is particularly noticeable and important among AA and
Hispanic persons with the ε3/ε4 genotype who do not have a significantly increased risk compared to
ethnically-matched persons lacking ε4 [26,27]. Notably, the protective effect of ε2 does not vary by
ethnicity, age, or sex [10]. Variability across populations in the risk of AD associated with genotypes
containing ε4 can be explained, in part, by differences in the ε4 allele frequency, i.e., groups with
a higher frequency of ε4 trend toward a lower risk of AD attributable to ε4 [28,29]. This pattern most
notably occurs in populations of African ancestry who have one of the world’s highest frequencies
of ε4 but the lowest prevalence of AD [10,28,30]. The basis for population differences in the AD/ε4
association is unknown, but several hypotheses have been proposed, including genetic modifiers within
or extant from the APOE locus and moderating influences of dietary and environmental factors [31].
To address this question, we investigated the ethnic-dependent risk of AD mediated by other APOE
single nucleotide polymorphisms (SNPs) in the coding and regulatory regions in a multi-ethnic sample.
We also examined the influence of APOE SNPs on brain structure, including cortical thickness and
hippocampal volume.
2. Materials and Methods
2.1. Study Participants
An East Asian (EastA) cohort, including 1308 AD patients and 1803 cognitively normal older adults,
from the Gwangju Alzheimer’s & Related Dementias (GARD) Study in Korea and 994 AD patients
and 971 controls from Japan was assembled by the National Research Center for Dementia (NRCD)
at Chosun University in Gwangju, Korea. A battery of neuropsychological tests that assess memory,
attention, language, as well as visuospatial and executive function, was administered to all individuals
(see the Supplementary Materials for details). The clinical diagnosis of probable AD was made
according to the National Institute Neurological and Communicative Disorders and Stroke–Alzheimer
Disease and Research Disorders Association (NINCDS-ADRDA) criteria [32]. Controls had no evidence
of neurological disease or impairment in cognitive function or activities of daily living. Individuals
who had a focal lesion on the brain MRI (magnetic resonance imaging), a history of head trauma,
or psychiatric disorder that could affect mental function were excluded. Subsets of this sample had
a brain MRI scan (139 AD cases, 921 controls), amyloid PET (positron emission tomography) imaging
scan (418 AD cases, 711 controls), or both (45 AD cases, 121 controls). The study protocol was approved
by the institutional review board of Chosun University Hospital, Korea. All volunteers or authorized
guardians for cognitively impaired individuals gave written informed consent before participation.
Data for an additional population-based sample of 14,322 Koreans (55.2% female) of age 40 years or
older (mean = 55.4 ± 9.7 years) were obtained from the Korean Genome and Epidemiology Study
(KoGES) [33,34]. Clinical and genetic information for EuroAs (8419 AD cases and 7417 controls)
and AAs (1523 AD cases and 3462 controls) was obtained from the Alzheimer’s Disease Genetics
Consortium (ADGC) (Table S1). PET imaging data were also obtained for 1012 EuroA participants
(568 AD cases and 444 controls) of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) from the
ADNI database (http://adni.loni.usc.edu) (Table S2).
2.2. Data Generation and Analysis
2.2.1. SNP Genotyping
Genomic DNA for 4150 Korean individuals was extracted from peripheral blood leukocytes
that were isolated from whole blood collected in EDTA tubes. The samples were genotyped using
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an Affymetrix Axiom KORV1. 0 Genome-wide genotyping array (Affymetrix®Axiom KORV1.0,
Santa Clara, CA, USA), which was designed and optimized for Korean content by the Center for
Genome Science, Korea National Institute of Health, Republic of Korea (4845–301, 3000–3031) [35].
The genotyping was performed at DNALink (Seoul, South Korea). APOE genotypes were derived from
allelic combinations of rs7412 and rs429358, which are included in the genotyping array. The genotype
data for 2022 Japanese were kindly provided by Dr. Takeshi Ikeuchi (Niigata University, Niigata, Japan).
Genotype data for 1250 ADNI participants were obtained from the ADNI database. Samples from
KoGES individuals were genotyped with the Affymetrix 5.0 (Affymetrix) (n = 8840), Affymetrix 6.0
(Affymetrix) (n = 1816), or Illumina Omni1-quad (Illumina, San Diego, CA, USA) (n = 3666) BeadChips.
2.2.2. Quality Control of Genome-Wide Data
Data were excluded for Korean NRCD and Japanese samples with individual call-rate <95%,
gender inconsistency between reported sex and analysis of X-chromosome SNPs, and extremely low
or high genome-wide heterozygosity (±3 SD from the mean). Samples with SNPs with a call-rate
<95%, Hardy-Weinberg equilibrium (HWE) test p-value <10−6, or minor allele frequency (MAF) <1%
were excluded. For the Korean population-based individuals, SNPs were excluded for which the call
rate <95%, HWE test p-value <10−5, and MAF <1%. Samples with genotype call-rate <95% and with
gender inconsistencies were also removed. Quality control procedures for the EuroA and AA datasets
are described elsewhere [36]. SNP genotypes for the EuroAs were imputed separately for each data
set using pre-phased reference haplotypes from the Haplotype Reference Consortium (HRC) panel
version 1.1 [37]. SNP genotypes for the EastAs and AA cohorts were imputed using the 1000 Genome
(Phase 3) reference panel. After imputation, the low-quality imputed SNPs (info score <0.5) were
removed [37–39]. The sequencing of the APOE promoter region for Korean samples demonstrated that
imputation accuracy of rs405509 was over 99%.
2.3. Statistical Genetic Analysis
2.3.1. Association of AD Risk with SNPs in the APOE Region
Association testing was performed in each dataset with SNPs in the APOE region encompassing
5.7 kb (19:45,406,947–19:45,412,650 based on build GRCh37) using logistic regression models that
included covariates for age and sex implemented in SPSS version 23.0 for windows (IBM Corp, Armonk,
NY, USA) and the R program, version 3.3.1 (https://www.r-project.org/). Models for the EuroA and
AA groups also included terms for the first three principal components (PCs) of ancestry calculated
previously [36] to account for population substructure. PC analysis was performed for the EastA
groups using the smartpca program with EIGENSOFT [40,41]. PCs identified by these analyses that
are significantly associated with AD were included in association test models for Koreans (n = 4),
Japanese (n = 5), and combined EastAs (n = 3). Analyses were conducted across all individuals and
within subgroups containing individuals with APOE genotypes ε3/ε3 and ε4/ε4 or ε3/ε4. Results for
each model were combined across datasets by meta-analysis within and across the ethnic group using
the metafor package [42]. Heterogeneity across datasets was evaluated by Cochran’s Q test and I2
statistics, and considered to be significant if Pheterogeneity (Ph) <0.05 and I2 >50%. Because no analyses
indicated significant heterogeneity, a fixed-effects model with inverse variance method was used to
combine effect estimates.
2.3.2. Follow-up Association Analyses with rs405509
We evaluated the interaction of APOE ε4 with rs405509 on AD risk by testing a model that included
the main effects and an interaction term, as well as age, sex, and PCs. To evaluate the effect of the APOE
promotor SNP, rs405509, genotypes in APOE isoform subgroups, we used a Cox proportional hazard
model in the cross-sectional data, including the GARD Study, Japanese, and ADGC EuroA subjects.
We used age as the time scale, with age at AD diagnosis as the event time for cases, and age at exam as the
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censoring age for controls, and adjusted for sex and ethnic group [43]. The influence of APOE isoform
and rs405509 genotypes on cortical thickness measures was assessed using general linear models (GLM)
implemented in the Surfstat toolbox (http://www.math.mcgill.ca/keith/surfstat/) in MATLAB (R2012a,
The Mathworks, Natick, MA, USA) with covariates sex, age, and field strength [44]. A random field
theory (RFT)-based correction for multiple point-wise cortical thickness comparisons was applied at the
cluster level with p = 0.05 as the significance threshold [45] (http://www.math.mcgill.ca/keith/surfstat/).
We also evaluated the effects of the ε4 and rs405509 genotypes on hippocampal volumes and anatomical
regions of interest (ROIs) using R, version 3.3.1 (https://www.r-project.org/). Hippocampal volume and
ROI differences among subgroups defined by APOE isoform and rs405509 genotypes were assessed by
analysis of covariance (ANCOVA) with APOE genotype as a fixed factor, and sex, age, field strength,
education, and intracranial volume (ICV) as covariates [46,47]. To compare the degree of ε4-driven
atrophy between EuroAs and EastAs, we conducted a t-test to compare the cortical thickness and
hippocampal volume measures between ε4/ε4 or ε3/ε4 and ε3/ε3 individuals within each ethnic
group [48]. Since cortical thickness and hippocampal volume are highly correlated and tests of these
outcomes are not independent, we applied a significance threshold of p < 0.05.
2.4. APOE Reporter Gene Assays
2.4.1. APOE Promoter Construct
Genomic DNA from the APOE promoter region (positions −1983 to +935) was amplified from
one AD patient with ε4/ε4 and rs405509-TT genotypes and one control with ε3/ε3 and rs405509-GG
genotypes) using the following primers: forward, 5′-GGGGTACCGAAAGCAGCGGATCCTTGAT
-3′; reverse, 5′-CCCCTCGAGCTTCCTGCCTGTGATTGGC -3′. The amplified DNA from each
subject was digested with KpnI and XhoI and ligated into the pGL3.basic vector (Promega,
Madison, WI, USA). PCR based site-directed mutagenesis of rs405509 (−219G/T) was carried
out to replace T by G for the construct from AD patient and G by T from control using
the following primers: T → G forward, 5’-GAGGAGGGTGTCTGGATTACTGGGCGAG-3’;
reverse, 5′- CTCGCCCAGTAATCCAGACACCCTCCTC -3′, G
→ T forward, 5’-GAGGAGGGTGTCTGTATTACTGGGCGAGG-3’;
5’-CCTCGCCCAGTAATACAGACACCCTCCTC-3’. The reactions were performed using PfuUltra
High-Fidelity DNA Polymerase (Agilent Technologies Inc, Santa Clara, CA, USA).
2.4.2. Luciferase Assay
HEK 293T cells were cultured in 12-well plates. After 24 h, the cells were co-transfected with 0.25µg
of pGL3 carrying the firefly luciferase reporter gene (Promega) and 0.25 µg of pCMV-β-galactosidase
(Clontech, Palo Alto, CA, USA) using TransFectin™ Lipid Reagent for 24 h. Transfected cells were
lysed with reporter lysis buffer (Promega). Luciferase and β-galactosidase activities were quantitated
by using a GloMax® Luminometer (Promega) and Epoch microplate spectrophotometer (BioTek
Instruments, Winooski, VT, USA), respectively. Luciferase activity for the APOE promoter was
determined by normalizing with β-galactosidase activity. We examined the allele-specific functional
impact of the promoter SNP rs405509 by measuring APOE expression using luciferase assays in HEK
cells with the APOE promoter constructs containing different rs405509 alleles. Results obtained from
three independent experiments were evaluated by t-test.
2.5. Human Postmortem Brain Tissues
Human postmortem cerebral cortical tissue specimens from eight ε3 homozygotes, one ε2/ε3
individual, four ε3/ε4 individuals, and two ε4/ε4 homozygotes were received from the Victorian Brain
Bank Network (VBBN). Nine human postmortem cerebellar tissue specimens (all ε3 homozygotes)
were obtained from The Netherlands Brain Bank (NBB), Netherlands Institute for Neuroscience,
Amsterdam (open access: http://www.brainbank.nl). Brain tissues collected by the NBB were
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obtained with written informed consent for a brain autopsy and use of the material and clinical
information for research purposes. Experimental procedures involving brain tissue are described in
the Supplementary Materials.
3. Results
3.1. Ethnic Variability in the Association of APOE ε4 with AD
The distributions of APOE genotypes and allele frequencies were significantly different between
AD cases and controls in all ethnic groups (Tables S3 and S4) with increasing odds of AD among carriers
of the ε4 allele in a dose-dependent manner and lower odds of AD among ε2 carriers (Table 1 and Tables
S5). Comparison of the APOE genotype-specific ORs across ethnic groups showed that the magnitude
of the effect of the ε3/ε4 on AD risk was similar among EastAs (OR (odds ratio) = 5.0, p = 2.6 × 10−152)
and EuroAs (OR = 3.8, p = 2.0 × 10−270), but higher than that for AAs (OR = 2.5, p = 1.3 × 10−35).
The odds of AD associated with ε4 homozygosity varied substantially across ethnic groups (OR = 25.1,
14.4, and 8.2 for EastAs, EuroAs, and AAs, respectively) (Table 1). Similar distributions of APOE
genotypes and patterns of association were observed in the EastA and EuroA brain amyloid imaging
study participants (Tables S6 and S7).
Table 1. Association of APOE ε4 with Alzheimer’s disease among East Asian, European ancestry,
and African American individuals.
Population N Control/AD
ε3/ε4 ε4/ε4
OR (95% CI) a p OR (95% CI) a p
East Asian b 19,398 17,096/2302 4.98 (4.4–5.6) 2.6 × 10−152 25.12 (19.0–33.5) 2.8 × 10−109
European ancestry
(ADGC) 15,836 7417/8419 3.83 (3.6–4.1) 2.0 × 10−270 14.35 (12.0–17.1) 2.3 × 10−187
African ancestry
(ADGC) 4985 3462/1523 2.49 (2.2–2.9) 1.3 × 10−35 8.17 (6.3–10.7) 3.0 × 10−54
Abbreviations: AD, Alzheimer’s disease; OR, odds ratio; CI, confidence interval; p, p-value; ADGC, Alzheimer’s
Disease Genetics Consortium. a ε3/ε3 is the reference genotype. b includes GARD (Gwangju Alzheimer’s & Related
Dementias) Study and Japanese subjects.
3.2. Identification of SNPs in the APOE Region Contributing to Ethnic Variability in AD Risk
We hypothesized that the ethnic differences in the effect size of ε4/ε4 on AD risk might be due to the
moderating effect of variants in the APOE region that have different frequencies across ethnic groups.
Furthermore, such variants would be progressively more or less frequent in EastAs, EuroAs, and AAs
to account for the observed decreasing effect of ε4/ε4 on AD risk in these groups, respectively [10].
To investigate this hypothesis, we screened the APOE region spanning the APOE promoter and 3’-UTR
surrounding the APOE coding region to identify SNPs showing a progressive 5% or greater difference
in allele frequency among the ethnic groups (Figure 1A and Table S8). Three out of 57 common SNPs
(MAF > 1%) in this region (Figure 1B) met the criteria and were significantly associated with AD risk in
the EastA group: rs449647 (p = 1.89 × 10−9), rs405509 (p = 2.5 × 10−8), and rs440446 (p = 1.08 × 10−18).
Among them, rs405509 showed the largest difference in allele frequencies among the population
samples included in this study; the T allele frequency was 0.739, 0.528, and 0.278 for the EastA, EuroA,
and AA groups, respectively (Figure 1C). These differences were more pronounced in the subgroup of
ε4 homozygotes. Large ethnic differences in allele and genotype frequencies were observed for rs449647
and rs440446; however, these differences were much smaller among ε4 homozygotes. Based on these
findings, subsequent analyses were focused on the APOE promoter SNP rs405509.
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SNP, single nucleotide polymorphism; MAF, minor allele frequency. 
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Figure 1. Single nucleotide polymorphisms (SNPs) in the APOE region modulate Alzheimer’s disease
risk associated with the apolipoprotein E (APOE) ε4/ε4 genotype. (A) Flow diagram showing the
strategy for screening SNPs. (B) APOE gene structure. (C) Genotype frequencies for rs449647 (−491
A/T), rs405509 (−219 T/G), rs440446 (+113 G/C), rs429358, and rs7412 among all individuals and ε4/ε4
individuals within East Asian, European ancestry, and African American groups. Abbreviations: SNP,
single nucleotide polymorphism; MAF, minor allele frequency.
3.3. APOE Promoter SNP, rs405509, Modulates the ε4 Association for AD
To investigate the joint influences of rs405509 and ε4 on AD risk, we analyzed the association
of APOE isoform genotype with AD within each rs405509 genotype and ethnic group. AAs were
excluded from these analyses due to small samples for several APOE-rs405509 genotype subgroups.
Results from these analyses showed increased odds of AD in a dose-dependent manner of the rs405509
T allele among ε4/ε4, but not ε3/ε4, compared to ε3/ε3 individuals (Table 2). In the EastA group,
the odds of AD associated with ε4/ε4 were substantially higher for TT individuals (OR = 27.02,
95% CI = 19.81–37.18, p = 8.80 × 10−94) compared to GT individuals (OR = 15.87, 95% CI = 6.32–39.49,
p = 2.62 × 10−9). A similar dose-dependent trend based on the number of T alleles was evident in
the EuroA group (TT: OR = 18.13, 95% CI = 14.02–23.44, p = 2.69 × 10−108; GT: OR = 12.63, 95% CI
= 9.41–16.94, p = 3.44 × 10−64; GG: OR = 8.35, 95% CI = 4.58–15.21, p = 4.07 × 10−12). Among ε3/ε3
and ε4/ε4 individuals, the term for the interaction of APOE and rs405509 genotypes was significant
in the EuroA group (OR = 1.40, 95%CI = 1.06–1.85, p = 0.17, Table S9). Although the interaction
was not significant in the EastA group (p = 0.19), the direction of effect was the same and stronger
than in EuroAs (OR = 1.82, 95% CI = 0.75–4.47), and the interaction test was more significant in the
combined EastA and EuroA groups (p = 0.0080, OR = 1.43, 95% CI = 1.10–1.87). The interaction
was attenuated but not significant among ε3/ε3 and ε3/ε4 individuals in EastAs or EuroAs. Survival
analysis by APOE isoform genotype (ε3/ε3, ε3/ε4, ε4/ε4) confirmed a significant inverse relationship
between age-at-onset and dosage of the ε4 in the combined group of EastAs and EuroAs (Figure 2),
regardless of rs405509 genotype (p < 0.0001 for ε3/ε4 and ε4/ε4 compared to ε3/ε3; p < 0.0001 for ε4/ε4
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compared to ε3/ε4), an observation consistent with many studies [6,10]. Rs405509 genotype had little
impact, if any, on age-at-onset among ε3/ε3 or ε3/ε4 individuals, whereas among ε4/ε4 individuals,
the age-at-onset distribution for rs405509 T allele homozygotes (hazard ratio, HR = 5.01, p = 4.94
× 10−259) was progressively younger than that for those with the GT (HR = 4.23, p = 1.17 × 10−132)
or GG genotypes (HR = 3.79, p = 1.87 × 10−28) (Figure 2 and Table S10). These results suggest that
rs405509 T-allele acts as a modulator of age at onset among ε4/ε4 individuals, consistent with our
association analysis.
Table 2. Modifying effect of rs405509 on association of APOE (apolipoprotein E) genotype and
Alzheimer’s disease.
Population rs405509 n
ε3/ε3 ε3/ε4 ε4/ε4
Odds Ratio
(95% CI) p
Odds Ratio
(95% CI) p
East Asian
TT 9770 Ref 5.13 (4.40–5.98) 5.10 × 10−98 27.02 (19.81–37.18) 8.80 × 10−94
GT 7941 Ref 4.55 (3.69–5.61) 1.09 × 10−45 15.87 (6.32–39.49) 2.62 × 10−9
GG 1681 Ref 3.55 (1.38–8.60) 0.006 NAa -
European
ancestry
(ADGC)
TT 4713 Ref 4.25 (3.71–4.88) 1.55 × 10−94 18.13 (14.02–23.44) 2.69 × 10−108
GT 7510 Ref 3.89 (3.49–4.34) 2.55 × 10−134 12.63 (9.41–16.94) 3.44× 10−64
GG 3385 Ref 3.39 (2.81–4.09) 4.87 × 10−37 8.35 (4.58–15.21) 4.07 × 10−12
Total
TT 14,483 Ref 4.62 (4.17–5.11) 2.60 × 10−187 20.96 (17.07–25.73) 7.69 × 10−186
GT 15,451 Ref 4.10 (3.55–4.74) 4.53 × 10−176 12.90 (9.75–17.07) 1.05 × 10−71
GG 5066 Ref 3.40 (2.83–4.08) 7.16 × 10−39 8.44 (4.66–15.27) 1.84 × 10−12
Abbreviations: CI, confidence interval; p, p-value; ref, reference; ADGC, Alzheimer’s disease Genetics Consortium.
a NA: result not available due to a very small number of controls with both ε4/ε4 and GG genotypes (n = 1). The odds
ratios were adjusted for age and sex.
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Figure 2. Rs405509 influences age at onset of Alzheimer’s disease. The effect of rs405509 genotype on
age at onset was evaluated by survival analysis using Cox regression models adjusted for sex. Curves
are shown f r indivi uals with t e following isoform and rs4 5509 genotype combinations:
ε4/ε4-TT (dark red line), ε4/ -GT (dotted gr e), ε4/ε4- G (gree line), ε3/ε4-TT (orange line),
ε3/ε4-GT (dotted light gray line), ε3/ε4-G (blue line), ε3/ε3-TT (purple line), ε3/ε3-GT (dotted light
blue line), and ε3/ε3-GG (black line).
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3.4. Association of APOE Polymorphisms with Brain Atrophy
To determine whether the observed ethnic differences in the effect of ε4/ε4 on AD risk extends to
AD-related structural brain changes, we evaluated the association of APOE genotype with several
brain MRI measures in the GARD EastA and ADNI EuroA samples (Table S11). We observed that ε4/ε4
individuals exhibited greater thinning in several cortical areas compared to ε3/ε3 individuals (Figure 3).
Surprisingly, cortical thinning in these regions was greater in EastA individuals than EuroA individuals
in both APOE genotype groups. Analysis of specific regions showed the largest differences (p < 0.01
for both ethnic groups) in the medial temporal cortex, precuneus, and hippocampus (Figure 3B–D,
and Table S12). The shrinkage in the medial temporal cortex and hippocampus among ε4/ε4 individuals
was significantly greater in EastAs than EuroAs (p < 0.05). Greater cortical thinning was also observed
in ε3/ε4 individuals compared to ε3/ε3 individuals in both EastA and EuroA groups (Figure S1),
although the genotype-associated differences were greater in EuroAs than EastAs (Table S13).
J. Clin. Med. 2019, 8, x 9 of 19 
 
3.4. Association of APOE Polymorphisms with Brain Atrophy 
To determine whether the observed ethnic differences in the effect of ε4/ε4 on AD risk extends 
to AD-related structural brain changes, we evaluated the association of APOE genotype with several 
brain MRI measures in the GARD EastA and ADNI EuroA samples (Table S11). We observed that 
ε4/ε4 individuals exhibited greater thinning in several cortical areas compared to ε3/ε3 individuals 
(Figure 3). Surprisingly, cortical thinning in these regions was greater in EastA individuals than 
EuroA individuals in both APOE genotype groups. Analysis of specific regions showed the largest 
differences (p < 0.01 for both ethnic groups) in the medial temporal cortex, precuneus, and 
hippocampus (Figure 3B–D, and Table S12). The shrinkage in the medial temporal cortex and 
hippocampus among ε4/ε4 individuals was significantly greater in EastAs than EuroAs (p < 0.05). 
Greater cortical thinning was also observed in ε3/ε4 individuals compared to ε3/ε3 individuals in 
both EastA and EuroA groups (Figure S1), although the genotype-associated differences were greater 
in EuroAs than EastAs (Table S13). 
 
Figure 3. APOE ε4/ε4-sensitive brain atrophy is greater in East Asians (EastA) compared to 
individuals of European ancestry (EuroA). (A) Cortical thinning maps in EastAs and EuroAs. A 
general linear model was applied to infer the point-wise cortical thickness differences using APOE 
genotype (ε4/ε4 vs. ε3/ε3) as a predictor adjusted for age, sex, and field strength covariates. 
Statistically greater thinning in ε4/ε4 compared to ε3/ε3 individuals is shown for the entorhinal and 
parahippocampal regions (encompassed in dotted black circles) and precuneus region (encompassed 
in blue circles). Average cortical thickness in the medial temporal cortex (entorhinal and 
parahippocampal regions (B)), precuneus (C), and hippocampus (D) was compared between APOE 
genotypes ε4/ε4 and ε3/ε3 in EastA and EuroA individuals. Data were normalized to ε3/ε3 and shown 
as percentages with error bars indicated above the bar plot (* p < 0.05, ** p < 0.01, *** p < 0.001). (E) 
Cortical thinning in EuroAs comparing individuals with combinations of rs405509-ε4/ε4 genotypes 
with the ε3/ε3 genotype using a general linear model and showing regional differences as described 
in Panel A. Average cortical thickness in the medial temporal cortex (entorhinal and parahippocampal 
regions, (F)), precuneus (G), and hippocampus (H) was compared between ε3/ε3 and either rs405509 
(TT)-ε4/ε4 or rs405509 (GG)-ε4/ε4 individuals. Data were normalized to ε3/ε3 and shown as a 
percentage with error bars indicated above the bar plot (* p < 0.05, **p < 0.01, *** p < 0.001). 
Abbreviations: GARD, Gwangju Alzheimer's and Related Dementias Study; EastA, East Asian; ADNI, 
Alzheimer’s Disease Neuroimaging Initiative; EuroA, European ancestry. 
Examination of the effect of rs405509 on AD-related brain changes in the EastA dataset (Figure 
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Figure 3. APOE ε4/ε4-sensitive brain atrophy is greater in East Asians (EastA) compared to individuals
of European ancestry (EuroA). (A) Cortical thinning maps in EastAs and EuroAs. A general linear
model was applied to infer the point-wise cortical thickness differences using APOE genotype (ε4/ε4
vs. ε3/ε3) as a predictor adjusted for age, sex, and field strength covariates. Statistically greater
thinning in ε4/ε4 compared to ε3/ε3 individuals is shown for the entorhinal and parahippocampal
regions (encompassed in dotted black circles) and precuneus region (encompassed in blue circles).
Average cortical thickness in the medial temporal cortex (entorhinal and parahippocampal regions
(B)), precuneus (C), and hippocampus (D) was compared between APOE genotypes ε4/ε4 and ε3/ε3
in EastA and EuroA individuals. Data were normalized to ε3/ε3 and shown as percentages with
error bars indicated above the bar plot (* p < 0.05, ** p < 0.01, *** p < 0.001). (E) Cortical thinning
in EuroAs comparing individuals with combinations of rs405509-ε4/ε4 genotypes with the ε3/ε3
genotype using a general linear model and showing regional differences as described in Panel A.
Average cortical thickness in the medial temporal cortex (entorhinal and parahippocampal regions,
(F)), precuneus (G), and hippocampus (H) was compared between ε3/ε3 and either rs405509 (TT)-ε4/ε4
or rs405509 (GG)-ε4/ε4 individuals. Data were normalized to ε3/ε3 and shown as a percentage with
error bars indicated above the bar plot (* p < 0.05, ** p < 0.01, *** p < 0.001). Abbreviations: GARD,
Gwangju Alzheimer’s and Related Dementias Study; EastA, East Asian; ADNI, Alzheimer’s Disease
Neuroimaging Initiative; EuroA, European ancestry.
Examination of the effect of rs405509 on AD-related brain changes in the EastA dataset (Figure 3E)
revealed that ε4/ε4-TT individuals showed significant reduction (p < 0.05) in the medial temporal
cortex (Figure 3F), precuneus (Figure 3G), and hippocampus (Figure 3H) compared to ε3/ε3 individuals.
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Further analysis in the EuroA dataset revealed that among individuals with the rs405509 TT genotype,
ε4 homozygotes exhibited significantly greater atrophy in the medial temporal cortex (F = 6.33,
p = 0.013), precuneus (F = 8.27, p = 0.005), and hippocampus (F = 18.13, p = 3.4 × 10−5) compared to ε3
homozygotes, whereas ε4 homozygotes showed no significant difference in any of the cortical regions
compared to ε3 homozygotes among individuals with the rs405509 GG genotype (Table 3). Similar
patterns were observed among EuroAs in comparisons of ε3/ε4-TT with ε3/ε3-TT individuals and
ε3/ε4-GG with ε3/ε3-GG individuals (Table 3) and in comparisons of ε3/ε4-TT or ε3/ε4-GG with ε3/ε3
individuals (Figure S1).
Table 3. Modifying effect of rs405509 genotype on the association of APOE ε4 with cortical atrophy in
European ancestry ADNI (Alzheimer’s Disease Neuroimaging Initiative) participants.
Region of Interest
rs405509-TT rs405509-GG
ε4/ε4 vs. ε3/ε3
(n = 175)
ε3/ε4 vs. ε3/ε3
(n = 239)
ε4/ε4 vs. ε3/ε3
(n = 128)
ε3/ε4 vs. ε3/ε3
(n = 161)
F-value p F-value p F-value p F-value p
Medial temporal cortex * 6.33 0.013 1.95 0.16 0.04 0.85 0.24 0.62
Precuneus 8.27 0.005 4.58 0.03 0.01 0.92 0.10 0.75
Hippocampal Volume 18.13 3.4 × 10−5 7.40 0.04 1.43 0.24 2.65 0.11
Abbreviations: p, p-value. * Medial temporal cortex includes both parahippocampal and entorhinal cortex.
3.5. Rs405509 Regulates APOE Expression
To determine if rs405509 is an expression quantitative trait locus (eQTL) for APOE, the effect of
rs405509 on APOE transcription was analyzed by reporter gene assay using APOE promoter fragments
from an AD patient with the rs405509 T allele and a cognitively normal person with the rs405509 G
allele. The rs405509 allele in each promoter region was changed to the alternative-allele by site-directed
mutagenesis and then subjected to a luciferase-based reporter gene assay (Figure 4A,B). The T to G
base substitution resulted in a 1.66-fold increase in APOE promoter activity (p < 0.01), whereas the G to
T substitution resulted in a 60% decrease in promoter activity (p < 0.01), indicating that the T allele
reduced APOE transcription compared to the G allele. Next, we performed Western blotting in brain
and blood specimens from ε3 and ε4 carriers who collectively have rs405509 TT, GT, and GG genotypes
to determine whether T-allele dependent expression of APOE occurred in these tissues (Figure 4C–J).
The level of apoE protein was significantly lower in cerebral cortex among TT individuals compared to
those with G-allele in a T-allele dose-dependent manner in ε3 carriers (p < 0.01 in Figure 4C,D) and ε4
carriers (p < 0.001 in Figure 4E,F). T-allele dose-dependent APOE expression in the cerebellum (p < 0.05
in Figure 4G,H) and blood (p < 0.05 in Figure 4I,J) was also evident in ε3/ε3 individuals. Taken together,
these results suggest that the modifying effect of rs405509 genotype on the association of APOE with
risk and age at onset of AD is due to its influence on the level of apoE protein.
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Figure 4. The rs405509 T-allele reduces APOE expression. To investigate whether rs405509 alleles
directly affect the APOE expression, the APOE promoter region was subjected to a reporter gene
assay. APOE promoter DNA fragments were cloned from an AD patient (A) and a cognitively normal
control subject (B). The rs405509 T-allele was changed to a G allele by site-directed mutagenesis
(A) and vice versa (B). The horizontal bar graphs show the relative intensities of APOE promoter
activity. Data represent mean ± SEM (n = 5, ** p < 0.01). (C–J) The rs405509-dependent apoE protein
level was assessed in human brain tissue and serum. (C, E, and G) Cerebral cortical and cerebellar
tissues were subjected to Western blotting with anti-apoE and anti-GAPDH antibodies to investigate
rs405509 genotype-dependent expression levels of apoE in the brain. The cerebral cortical tissues
in panel C were from ε3 homozygotes except for one ε2/ε3 individual (lane 1). The cortical tissues
in panel E were from individuals with ε3/ε4 (lanes 1, 2, 4, and 5) or ε4/ε4 (lanes 3 and 6) genotypes.
All cerebellar tissues in panel G were from ε3 homozygotes. (D and H) Relative expression of APOE in
cerebral cortex and cerebellum among ε3 carriers stratified by rs405509 genotype (G/G, G/T, and T/T)
with G/G used as the reference and GAPDH used as a normalized control. Data represent mean
± SEM. (F) Relative expression of APOE in cerebral cortex among ε4 carriers stratified by rs405509
genotype (G/T and T/T) with G/T used as the reference and GAPDH used as a normalized control.
Data represent mean ± SEM. (I) Blood samples were subjected to Western blotting with anti-apoE,
anti-apoB, anti-apoC1, and anti-Transferrin antibodies to investigate rs405509 genotype-dependent
expression of apoE. (J) Relative expression of apoE in human serum among ε3/ε3 individuals stratified
by rs405509 genotype with G/G used as the reference. Data represent mean ± SEM. * p < 0.05,
** p < 0.01, *** p < 0.001. Abbreviations: ApoE, Apolipoprotein E; ApoC1, Apolipoprotein C1; ApoB,
Apolipoprotein B; GAPDH, Glyceraldehyde-3-Phosphate Dehydrogenase.
4. Discussion
Although the APOE ε4 allele is one of the most well-established AD risk factors and the genetic
variant that by far confers the strongest effect on disease risk [6,10,49], most studies of this association
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in non-EuroA populations have not precisely quantified for APOE genotype-associated risks for ε4
heterozygotes and ε4 homozygotes with notable exceptions of AAs [10,27], Caribbean Hispanics [50],
Indians [51], and Han Chinese [52]. Similar to Chinese [52], our study showed that the effect of ε4
on AD risk was stronger in Koreans and Japanese than in EuroAs and other non-EuroA populations,
including AAs, Indians, and Israeli-Arabs [53]. Ethnic differences in the effect size of this association
might be due to differences in allele frequency such that the proportional difference in the ε4 frequency
between cases and controls resulted in a larger odds ratio even though the absolute difference in the
allele frequency was similar across the population. In other words, in comparison to EuroAs, the ε4/AD
association was stronger in EastAs who had a lower ε4 frequency and weaker in AAs who had a higher
ε4 frequency. Alternatively, lifestyle, diet, and other genetic or non-genetic factors may account for
differences in the association across populations [54,55].
Consistent with findings in previous studies conducted in EuroAs [56–58], we demonstrated
that ε4 accelerated the cortical thinning in regions of the entorhinal cortex, parahippocampal cortex,
and precuneus in EastA individuals. Surprisingly, cortical and hippocampal atrophy observed in ε4/ε4
individuals was more severe in EastAs than EuroAs. There is no obvious explanation to account for
ethnic differences, but this observation is consistent with the idea of interaction of the ε4/ε4 genotype
with exogenous or other genetic factors.
We hypothesized that the difference in ε4/ε4-mediated AD risk between populations might be due
in part to differences in genetic background. Numerous studies have suggested that variants within
the APOE promoter and intronic regions, in particular, promoter SNPs rs449647 (-491A/T) and rs405509
(−219T/G), independently of or synergistically with APOE ε4 modulate AD risk [59–62], although
other studies were unable to replicate these findings [63–68]. In addition, rs405509 has been reported
to interact with ε4 to accelerate cognitive impairment in non-demented elderly [69]. We, therefore,
limited our testing to SNPs within the interval between TOMM40 and APOC1 (which includes the
APOE coding region, promoter, and 3’-UTR), whose allelic frequencies vary progressively by at least
5% across EastAs, EuroAs, and AAs and may modulate (and are most likely responsible for ethnic
differences in) the effect of ε4 on AD risk. Through a series of filtering steps, we narrowed a pool of
57 SNPs in this region to two APOE promoter SNPs (rs405509 and rs449647) and one APOE intronic
SNP (rs440646) for formal testing of our hypothesis. Among these SNPs, only rs405509 showed
a consistently large difference in genotype frequencies across ethnic groups that could account for the
observed variability in the magnitude of effect of ε4 on AD risk (Figure 1C), particularly the effect
of the rs405509 TT genotype among ε4/ε4 individuals that was evident in both EastAs and EuroAs
(Table 2). Individuals with both of these homozygous genotypes also had significantly younger-onset
ages than those with other rs405509 genotypes (Figure 2).
Several studies reported association of rs405509 with AD risk [60,62,70,71], but this relationship is
controversial [64,66–68,72]. However, many of these studies considered rs405509 as an independent
risk factor for AD without accounting for the high linkage disequilibrium between this SNP and the
SNPs that define the APOE isoform genotypes. Consistent with our findings, Ma et al. demonstrated
that rs405509-T homozygosity modulated the ε4 effect on cognitive performance and brain gray matter
atrophy among the elderly [73].
Our findings also suggested that the synergistic effect of rs405509-TT and ε4/ε4 extended to
AD-related neurodegeneration. Individuals with both of these genotypes, but not those with the
combination of GG and ε4/ε4, exhibited significantly greater atrophy in the medial temporal cortex,
precuneus, and hippocampus compared to ε3 homozygotes with the corresponding rs405509 genotypes.
These observations are consistent with results of a prior study showing an accelerated age-related
reduction of thickness in the left parahippocampal gyrus among TT non-demented Chinese elders
compared with the G-allele carriers from the same cohort; however, this finding might be confounded
with the unadjusted effect of ε4 [74].
Our reporter gene assay experiments using APOE promoter fragments from an AD patient
with the rs405509 T allele and a cognitively normal person with rs405509-G allele demonstrated that
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the TT genotype lowered apoE expression in human brain and serum. The assays involving the
replacement of the T with the G allele or vice-versa confirmed that an APOE gene with the T allele
in the promoter was less expressed. Moreover, we demonstrated a significantly lower level of apoE
protein among individuals with the rs405509 TT genotype compared to those with the GG and GT
genotypes. Taken together, these results suggest that the increased risk of AD, a tendency toward
earlier onset of disease symptoms, and a greater degree of cortical degeneration among individuals
with the TT and ε4/ε4 genotypes are direct consequences of reduced expression of APOE. Recently,
longitudinal cohort studies including more than 75,000 individuals found that low levels of apoE were
associated with increased risk of developing AD and dementia more generally in the future [75,76],
supporting our observation that the reduced apoE level in ε4 homozygotes with rs405509 TT genotype
increased the onset of AD. It has also been shown that brain amyloid load is inversely correlated with
APOE expression level and that APOE expression is lower in AD cases than controls [77].
Some of the findings reported here should be interpreted cautiously in light of several limitations
to our study. The KoGES population controls were not cognitively screened and on average were 17
years younger than Korean controls from the GARD Study. However, subject misclassification would
likely bias the results toward the null hypothesis. Our sample of EastAs lacked the power to show
statistically significant differences in the magnitude of the moderating effect of each rs405509 genotype
on the association of ε4 homozygosity on AD risk, age at onset, and AD-related neurodegeneration,
although the magnitude and direction of effects were comparable to those for the much larger EuroA
sample. The odds of AD associated with ε4 homozygosity among EastAs with the rs405509-GG
genotype could not be estimated due to small cell sizes. The relatively small number of AAs and the
low frequency of rs405509-TT in that group (8.2%) did not allow testing of this interaction in AAs.
In addition, the association findings with rs405509 might not be causal because they could be due to
linkage disequilibrium with an untested functional variant in this region. However, our findings in
support of rs405509 genotype-specific effects on the association of APOE and AD risk were validated by
results, showing an influence of rs405509 genotype on apoE levels in human brain and blood, and the
reporter gene assay experiments. Finally, we did not have a sufficient number of subjects with both
APOE ε4/ε4 and rs405509-GG genotypes to make the important comparison of the differential effects of
rs405509 genotypes on APOE expression in the ε4/ε4 group. That said, there is no expectation that the
impact of the promoter SNP on APOE expression would vary by APOE isoform; if there was any effect,
it would be on transcription which would unlikely be impacted by the coding SNPs that determine the
apoE isoforms. Although we demonstrated that the rs405509 T allele lowered the apoE level in ε3
homozygotes and ε4 carriers, but we were unable to evaluate this relationship in ε4 homozygotes due
to limited sample size. Thus, it is reasonable to conclude that reduced APOE expression in the brain or
blood of subjects lacking ε4 does not increase AD risk or that the influence of rs405509 genotype on
expression of APOE is even greater among subjects who are APOE ε4/ε4. The latter explanation is
consistent with evidence that ε4 homozygotes have greatly reduced apoE levels compared to those
with other APOE genotypes [75,78,79].
In conclusion, we confirmed previous findings that the risk of AD associated with homozygosity of
the APOE ε4 allele is greater in EastAs than EuroAs or AAs. Although this observation can be explained
in part by population differences in the ε4 frequency, the ethnic difference in the ε4/ε4-mediated
increased risk for AD and neurodegeneration is likely a direct consequence moderating effects on APOE
expression by rs405509 genotypes, whose frequencies vary widely across EastAs, EuroAs, and AAs.
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